Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. Further, the company's products under development include Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir; and Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. The company was incorporated in 1972 and is based in Mumbai, India.
Stock data | 2023 | Change |
---|---|---|
Price | $1.60 | N/A |
Market Cap | $25.30M | N/A |
Shares Outstanding | 15.83M | 0.00% |
Employees | 523.00 | N/A |
Shareholder Equity | 1.52B | 0.93% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 2.00 | N/A |
P/S Ratio | 0.58 | N/A |
P/B Ratio | 0.02 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0001 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $43.60M | N/A |
Earnings | $151.30K | N/A |
EPS | 0.8 | N/A |
Earnings Yield | 0.5006 | N/A |
Gross Margin | 0.1917 | N/A |
Operating Margin | 0.0399 | N/A |
Net income margin | 0.0035 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $42.84M | N/A |
Total Debt | $10.55M | N/A |
Cash on Hand | $320.26K | N/A |
Debt to Equity | 0.0163 | 15.69% |
Cash to Debt | 0.0304 | 36.55% |
Current Ratio | $1.25 | -12.15% |